RT Journal Article
SR Electronic
T1 SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2520
DO 10.1183/13993003.congress-2021.PA2520
VO 58
IS suppl 65
A1 Joaquim Mullol
A1 Giorgio Walter Canonica
A1 Martin Wagenmann
A1 Andre Coste
A1 Peter Hellings
A1 Scott Nash
A1 Siddhesh Kamat
A1 Urvi Mujumdar
A1 Jérôme Msihid
A1 Asif H Khan
A1 Shahid Siddiqui
A1 Juby A Jacob-Nara
A1 Yamo Deniz
A1 Paul Rowe
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA2520.abstract
AB Background: Chronic rhinosinusitis with nasal polyps is a predominantly type-2 mediated inflammatory disease with high symptom and quality of life burden. Dupilumab significantly improved 22-item Sino-Nasal Outcome Test (SNOT-22) total score vs placebo (PBO) in SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454).Objectives: Post hoc analysis of pooled SINUS-24 and SINUS-52 to identify the SNOT-22 items most important to patients (pts), assess the effect of dupilumab on these items, and association with objective disease measures.Methods: Nasal polyp (NPS) and Lund-Mackay (LMK) scores were assessed in pts with and without improvement at Wk 24 in the SNOT-22 items ranked most important by pts at baseline (BL).Results: Decreased sense of smell/taste and nasal blockage were the most important SNOT-22 items at BL (cited important by 87% and 82% of pts, respectively). More dupilumab (N=438) vs PBO (N=286) pts improved in these items at Wk 24 (smell/taste: 76.7% vs 30.4%; nasal blockage: 79.5% vs 44.4%). Dupilumab significantly improved NPS and LMK in all pts regardless of improvement in SNOT-22 items, with the greatest treatment effect seen in pts who had an improvement (Table below).Conclusions: A higher percentage of dupilumab-treated pts improved in symptoms most important to pts (smell/taste; nasal blockage) vs PBO. Improvement in these symptoms signals greater improvement in objective measures (LMK and NPS). SNOT-22 item improvement (Wk 24)Least squares mean difference vs PBO (Wk 24)Smell/tasteYes/noNasal blockageYes/noNPS–1.78*/–1.19*–1.90*/–1.01*LMK–5.77*/–4.26*–6.22*/–3.28**P<0.0001 vs PBOFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2520.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).